These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 35144338)

  • 1. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
    Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases.
    Tamura K; Yoshida T; Masuda K; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
    ESMO Open; 2023 Aug; 8(4):101594. PubMed ID: 37517364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.
    Wu H; Zhang Q; Zhai W; Chen Y; Yang Y; Xie M; Huang Z; Xu Y; Li H; Gong L; Yu S; Fan Y; Chen K
    Lung Cancer; 2024 Feb; 188():107475. PubMed ID: 38266613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.
    Arrieta O; Hernandez-Martinez JM; Montes-Servín E; Heredia D; Cardona AF; Molina-Romero C; Lara-Mejía L; Diaz-Garcia D; Bahena-Gonzalez A; Mendoza-Oliva DL
    Cancer Biomark; 2021; 32(2):123-135. PubMed ID: 34057135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status.
    Xu H; Chen H; Kong J; Zhang Y; Liu S; Yang G; Yang L; Wang Y
    Ann Transl Med; 2021 Jun; 9(11):937. PubMed ID: 34350252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
    Miyawaki T; Kenmotsu H; Yabe M; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Deguchi S; Mitsuya K; Naito T; Murakami H; Mori K; Harada H; Hayashi N; Takahashi K; Takahashi T
    Invest New Drugs; 2021 Dec; 39(6):1732-1741. PubMed ID: 34259953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
    Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
    Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study.
    Turnsek N; Devjak R; Edelbaher N; Osrajnik I; Unk M; Vidovic D; Jeric T; Janzic U
    Radiol Oncol; 2022 Aug; 56(3):371-379. PubMed ID: 35853681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM; Park K
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
    Yang JCH; Kim SW; Kim DW; Lee JS; Cho BC; Ahn JS; Lee DH; Kim TM; Goldman JW; Natale RB; Brown AP; Collins B; Chmielecki J; Vishwanathan K; Mendoza-Naranjo A; Ahn MJ
    J Clin Oncol; 2020 Feb; 38(6):538-547. PubMed ID: 31809241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes of Patients with Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis in the Modern Target Therapy Era.
    Wang Y; Li J; Liu T; Ge M; Ji X; Chu Z; Zhan Q; Liang X; Zhou X
    World Neurosurg; 2023 Feb; 170():e500-e509. PubMed ID: 36396052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
    Walia M; Singhal MK; Kamle MS
    Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
    Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
    Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.
    Li Y; Xu Z; Wang S; Zhu Y; Ma D; Mu Y; Ying J; Li J; Xing P
    Thorac Cancer; 2022 Aug; 13(15):2201-2209. PubMed ID: 35778830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
    Yu X; Sheng J; Pan G; Fan Y
    Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
    Wang X; Cai J; Zeng Z; Liu A
    BMC Cancer; 2021 Jul; 21(1):873. PubMed ID: 34330231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
    Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D
    Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.